Risk Sentiment at a Crossroads.. What Global Volatility Means for the GCC
Lilly’s Kisunla (donanemab-azbt) showed growing benefit over three years in
Findings from the TRAILBLAZER-ALZ 2 long-term extension study highlight Kisunla continued to demonstrate slowing of decline, with most participants having completed treatment Data underscores the value of early intervention and supports a limited duration dosing approach Read More



